CURRENT
ISSUE
1616

On December 18, 2020, the FDA issued an Emergency Use Authorization (EUA) for the Moderna mRNA-based vaccine for prevention of COVID-19 in persons ≥18 years old. The Pfizer-BioNTech mRNA-based vaccine received an FDA EUA for the same indication in persons ≥16 years old on December 11, 2020.1

CLINICAL STUDY — Issuance of the EUA was based primarily on the results of an observer-blind trial in which 30,420 subjects ≥18 years old were randomized 1:1 to receive the Moderna vaccine or placebo at 0 and 4 weeks. Immunocompromised persons and those with a history of SARSCoV-2 infection were excluded. There were 11 cases of COVID-19 among subjects who...  Continue reading

More from Issue 1616
Previous Issue: 1615      January 11, 2021
Coming Soon
Twirla - A New Contraceptive Patch
Pitolisant (Wakix) for Excessive Daytime Sleepiness
Osilodrostat (Isturisa) for Cushing’s Disease
Sacituzumab Govitecan (Trodelvy) for Metastatic Triple-Negative Breast Cancer
Drugs for Parkinson's Disease
Search
Donate
Subscribe
Conversation
Follow us   Twitter LinkedIn YouTube Blog RSS   Email Alerts
FROM
ISSUE
1616

Treatment of community-acquired pneumonia (CAP) is usually empiric, with selected antibiotic regimens directed against some of the most common causative pathogens. Recommended empiric regimens are listed in Table 2; recommended antibiotic dosages for treatment of CAP are listed in Tables 3 and 4. Joint guidelines for treatment of CAP by the American Thoracic Society and the Infectious Diseases Society of America ... Continue reading

 Tweets